eMedicine Specialties > Neurology > Neuromuscular Diseases

Stiff Person Syndrome

Author: Nancy Rodgers-Neame, MD, Assistant Professor, Department of Pharmacology and Therapeutics, University of South Florida, Florida Comprehensive Epilepsy and Seizure Disorders Program
Contributor Information and Disclosures

Updated: Mar 20, 2006

Introduction

Background

Stiff person syndrome is rather unique among neurologic diagnoses because of its lack of significant similarity to any other neurologic diseases. Although rare, once observed it is quite unforgettable. Possibly the closest related disease is tetanus because both conditions affect peripheral inhibition via central mechanisms and both conditions inhibit central gamma-aminobutyric acid (GABA) systems.

In 1956, Moersch and Woltmann, who also coined the term stiff man syndrome, first clearly described stiff person syndrome as a neurologic clinical entity at the Mayo Clinic. The eponym for this syndrome, Moersch-Woltmann syndrome, is one of the few instances in which the eponym may be the most inclusive and at the same time most appropriately limiting name for the disease. Stiff person seems to exclude babies, and stiff man is inappropriate for children and women; perhaps stiff individual most perfectly describes the affected patient.

Clinically, stiff person syndrome is characterized by muscle rigidity that waxes and wanes with concurrent spasms. Usually, it begins in the axial muscles and extends to the proximal limb muscles, but the severity of the limb muscle involvement may overwhelm the axial muscle involvement (stiff limb syndrome).

Some confusion has also ensued as a result of cases that include other neurologic findings, such as encephalomyelitis or cerebellar deficits, in addition to the classic clinical syndrome. To further confuse matters, the most common pathologic correlate, anti–glutamic acid decarboxylase (GAD) antibodies, have been associated with a wide range of human disease, including diabetes mellitus and seizures.

Pathophysiology

Endocrinologists were excited by a discovery in the 1980s of an antibody to a 65-kd protein that was strongly associated with adult-onset diabetes mellitus type 2. It is found in a particularly large subset of patients with type 2 diabetes, and endocrinologists hoped that it would be the major breakthrough needed to cure this disease in millions of patients worldwide. They were disappointed to find that the 65-kd protein was GAD, an enzyme largely found in the central nervous system (CNS), and, unfortunately, the pathophysiologic link remains unclear.

Since that time, the antibody has been found in a number of neurologic diseases, a scenario that is easier to understand, with the pathophysiologic link easier to explain. The range of diseases encountered includes seizures, cerebellar dysfunction, cortical dysfunction, and myelopathy, but the association between function of the enzyme and the consequence of the disease is most clear in stiff person syndrome. Spinal interneurons function to inhibit spontaneous discharges from spinal motor neurons, primarily through the action of glycine. However, this is only one inhibitory input for the motor pathway that includes GABA-mediated inhibition from the cortex, brain stem, and cerebellum. If GAD function is inhibited significantly, then GABA available for these functions is decreased and muscles become continuously stimulated by the motor neurons. Additional possible pathophysiologic etiologies in patients negative for GAD antibody include postsynaptic elements such as synaptophysins and GABA-transaminase.

Glutamate is an excitatory amino acid synthesized from glucose via the Krebs cycle. It has several fates within the cell. Glutamate can be packaged for release from synaptic clefts, and it can be acted on by several transaminases to transform it to either glutamine or GABA. Following release from the synapse, glutamate is absorbed either by reuptake mechanisms by the neurons or, more commonly, by astrocytes. Glutamic acid decarboxylase is nearly ubiquitous in the CNS and is located in or near the synaptic button. It is rate limited primarily by the availability of free glutamate. However, GAD is not the only source of GABA. The Krebs cycle also serves to synthesize GABA via GABA-transaminase.

However, GAD antibodies alone appear to be insufficient to cause stiff person syndrome, some patients clearly have antibody-negative disease, and GAD antibodies are associated with a broad spectrum of disease; consequently, GAD clearly forms only part of the pathophysiology of stiff person syndrome. Possibly, postsynaptic GABA-ergic mechanisms, such as the synaptobrevins involved in tetanus, are involved. Research continues to progress on this interesting subject (Blum, 1991; Ellis, 1996; Lernmark, 1996; Levy, 1999; Stayer, 1998; Zeigler, 1998).

Frequency

International

The frequency of stiff person syndrome worldwide and in the United States is unknown, but the syndrome is rare.

Mortality/Morbidity

Complications of this disease are multifaceted and may occur at any stage of the disease. In general, complications are responsible for the mortality and morbidity and are discussed in more detail in Complications.

Babies with stiff baby syndrome are at particularly high risk of sudden infant death and require monitoring.

  • Complications of baclofen pump failure can occur. Cataclysmic exacerbations of the disease have been reported due to baclofen pump failure. At least one death has been reported. In addition, rare malfunctions of the baclofen pump have been associated with excessive release of baclofen intrathecally also resulting in death or permanent disability.
  • Psychiatric morbidity from this disease is common. The unpredictability of symptoms and the linkage to stressful events only serve to exacerbate the situation. In addition, GABA mechanisms subserve many of the brain's emotional centers, which may contribute significantly to the psychiatric symptomatology.
  • Musculoskeletal complications are common, particularly in later stages of the disease. Joint deformity, joint dislocation, joint contracture, skeletal fracture, and muscle rupture have been reported.

Race

No differentiation among races has been reported to date.

Sex

Frequency and severity are nearly equal in males and females, but some series indicate a greater frequency in females. In general, autoimmune diseases are more frequently seen in females.

Age

  • The syndrome occurs in children younger than 3 years, most commonly in infants.
  • Onset in adults is most frequent in the third to fifth decades of life.

Clinical

History

  • Stiff person syndrome
    • Early stages
      • Stiff person syndrome usually begins insidiously in the axial muscles, and, if the patient is referred at an early stage, little objective findings may be found at the initial presentation.
      • In the initial stage of the disease, the patient has an exaggerated upright posture and may report back discomfort or stiffness or pain in the entire back, which is worse with tension or stress.
      • Patients may report disturbed sleep because, although the stiffness is relieved with sleep, when the patient transitions from rapid eye movement (REM) to stage 1 or 2 sleep they may lose the relief from the spasms, which may awaken them.
      • In some patients in the early stages, brief episodes of rather dramatic severe worsening that resolve spontaneously within hours or days may occur. Unfortunately, because of the subtle findings and apparent strong psychological components in the early stages, the patients are labeled as psychogenic, and effective treatment is often delayed.
    • Later stages
      • Later in the disease, proximal limb muscles also begin to be involved, particularly when the patient is stimulated, surprised, angered, upset, or frightened. This sort of stimulus may evoke painful severe spasms in the proximal arm and leg muscles that resolve slowly. The patient begins to move very slowly because rapid movement induces severe spasms. Even the distal extremities may become involved when moved rapidly.
      • Exaggerated lumbar lordosis is present combined with contraction of abdominal muscles.
      • Not surprisingly, depression has been noted as a comorbidity at this stage. The patient's quality of life is affected severely at this point, making it difficult or impossible to drive, work, or have a satisfying social life.
    • End stages
      • In the end stages of the disease, few muscles in the body are spared. Trismus is absent. However, facial and pharyngeal muscles may be affected markedly.
      • Joint deformities may occur. Skeletal fractures and muscle ruptures may occur during spasms.
      • Postsurgically, abdominal incisions are at risk of spontaneous rupture. Eating, simple movement, and other simple activities of daily living (ADLs) may be problematic.
  • Stiff baby syndrome
    • The clinical presentation of stiff baby syndrome is somewhat different.
    • Babies and young children are less rigid between attacks. Involvement of the distal muscles is often more evident, particularly during paroxysms. Opisthotonic posturing is more prominent.
    • Startle or stress is a frequent and prominent precipitant of the attacks.
    • Its clinical characteristics are within a broader descriptive category known as hyperekplexia. Differentiation of a particular case as stiff baby syndrome sometimes is considered dependent upon the presence of anti-GAD antibodies. In addition, stiff baby syndrome may be more persistent or more frequently recurrent, although this is not invariable.
    • Diagnosis can also be more complex because other etiologies (eg, other neuromuscular disorders, seizures, withdrawal or intoxication from maternal drug abuse) need to be excluded.
  • Associated diseases
    • Diabetes mellitus: Although different epitopes for the GAD antibodies in diabetes have been identified, stiff person syndrome and diabetes have demonstrated comorbidity. This comorbidity occurs in association with a finding of positive GAD antibodies. Early distal involvement and involvement of a single limb is more frequent in patients with diabetes mellitus. Stiff person syndrome has also been associated with diabetes mellitus and ICA 105 pancreatic autoantigen with and without the presence of anti-GAD antibodies.
    • Thyroiditis: An association with thyroiditis has been described. This may be due to comorbidity of multiple autoimmune entities or may be a more direct association. At least one group has suggested a link due to neuromuscular hyperactivity.
    • Breast cancer: A variant of stiff person syndrome occurs rarely in patients with breast cancer. The antibodies involved are to a synaptic protein, amphiphysin. Anti-GAD antibodies are absent.
    • Epilepsy: Anti-GAD antibodies have been described in patients with medication-resistant focal epilepsies. In one series, 4 of 19 patients with anti-GAD–positive stiff person syndrome were also found to have localization-related epilepsy.
    • Cerebellar ataxia: A number of case studies report the presence of cerebellar ataxia (with or without stiff person syndrome) associated with anti-GAD antibodies.
  • A form of familial spastic cerebral palsy has been described with a missense mutation in the GAD-67 gene. This is a different isoform of glutamic decarboxylase; however, it demonstrates that the pathophysiology of stiff person syndrome is likely due to abnormalities in the function of glutamic acid decarboxylase.

Physical

In general, increased muscle tension, which is more marked proximally than distally, is present. Less frequently, lower extremities are most affected. More rarely, upper and lower extremities are affected. In people with diabetes, one limb may be affected, sparing other muscle groups. In most if not all patients, opposing muscle groups are noted to be tense, and tonic contraction with long relaxation times may be noted following percussion of the muscle. In most patients, the neurologic examination findings are otherwise normal. Variations and stages are noted below.

  • Early in the disease, patients may report stiffness of the back and sometimes the neck; very little objective findings are revealed. Patients may walk and sit with an exaggerated upright posture (classic "tin-soldier" appearance).
  • Later in the disease, response to stimuli becomes marked. Startle may lead to very uncomfortable and prolonged spasms. The symptoms worsen significantly with stress or anxiety, and the worsening of symptoms causes anxiety, often causing a disturbing self-perpetuating cycle.
  • Late stages and acute exacerbations of the disease are accompanied by crippling involvement of the extremities. Skeletal fractures and muscular rupture have been observed in late stages of disease
  • One variation of the disease known as stiff limb syndrome is observed more frequently in patients with diabetes mellitus. In this variation, the axial involvement is less marked, and one or (rarely) more extremities are affected.
  • In stiff baby syndrome, distal findings may be more pronounced than in adults. Smaller babies may have increased tonic extension of the leg at the hip. Younger patients frequently have a more pronounced response to startle than adults, and hyperekplexia must be considered in the differential.

Causes

See Pathophysiology.

Currently, 3 autoantibodies associated with stiff person syndrome are identified. The idiopathic form is most often associated with glutamic acid decarboxylase antibodies. The paraneoplastic form is most often associated with amphiphysin antibodies. One case report identifies gephyrin antibodies associated with stiff person syndrome.

More on Stiff Person Syndrome

Overview: Stiff Person Syndrome
Differential Diagnoses & Workup: Stiff Person Syndrome
Treatment & Medication: Stiff Person Syndrome
Follow-up: Stiff Person Syndrome
References

References

  1. Aso Y, Sato A, Narimatsu M. Stiff-man syndrome associated with antecedent myasthenia gravis and organ-specific autoimmunopathy. Intern Med. Apr 1997;36(4):308-11. [Medline].

  2. Barker RA, Revesz T, Thom M. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. Nov 1998;65(5):633-40. [Medline].

  3. Blum P, Jankovic J. Stiff-person syndrome: an autoimmune disease. Mov Disord. 1991;6(1):12-20. [Medline].

  4. Brashear HR, Phillips LH 2nd. Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff-man syndrome. Neurology. Oct 1991;41(10):1588-92. [Medline].

  5. Brown P, Rothwell JC, Marsden CD. The stiff leg syndrome. J Neurol Neurosurg Psychiatry. Jan 1997;62(1):31-7. [Medline].

  6. Butler MH, Solimena M, Dirkx R Jr, et al. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med. Dec 1 1993;178(6):2097-106. [Medline].

  7. Butler MH, Hayashi A, Ohkoshi N. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron. May 2000;26(2):307-12. [Medline].

  8. Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff- person syndrome. Neurology. Nov 28 2000;55(10):1531-5. [Medline][Full Text].

  9. Dalakas MC, Li M, Fujii M. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology. Sep 11 2001;57(5):780-4. [Medline].

  10. Dalakas MC. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes. Clin Rev Allergy Immunol. Dec 2005;29(3):255-69. [Medline].

  11. Daw K, Ujihara N, Atkinson M, Powers AC. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol. Jan 15 1996;156(2):818-25. [Medline].

  12. De Camilli P, Thomas A, Cofiell R. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med. Dec 1 1993;178(6):2219-23. [Medline].

  13. Dinkel K, Meinck HM, Jury KM, et al. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol. Aug 1998;44(2):194-201. [Medline].

  14. Ellis TM, Atkinson MA. The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat Med. Feb 1996;2(2):148-53. [Medline].

  15. Fiol M, Cammarota A, Rivero A. Focal stiff-person syndrome. Neurologia. Feb 2001;16(2):89-91. [Medline].

  16. Floyd S, Butler MH, Cremona O. Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. Mol Med. Jan 1998;4(1):29-39. [Medline].

  17. Gerschlager W, Schrag A, Brown P. Quality of life in stiff person syndrome. Mov Disord. Sep 2002;17(5):1064-7. [Medline].

  18. Goppert D, Gardill K, Beischer W. [The stiff-man syndrome with diabetes mellitus type 1 and autoimmune thyroiditis]. Dtsch Med Wochenschr. Jul 7 2000;125(27):826-9. [Medline].

  19. Hayashi A, Nakamagoe K, Ohkoshi N, et al. Double filtration plasma exchange and immunoadsorption therapy in a case of stiff-man syndrome with negative anti-GAD antibody. J Med. 1999;30(5-6):321-7. [Medline].

  20. Ishida K, Mitoma H, Song SY, et al. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol. Aug 1999;46(2):263-7. [Medline].

  21. Johnstone AP, Nussey SS. Direct evidence for limited clonality of antibodies to glutamic acid decarboxylase (GAD) in stiff man syndrome using baculovirus expressed GAD. J Neurol Neurosurg Psychiatry. May 1994;57(5):659. [Medline].

  22. Lenti C, Bognetti E, Bonfanti R. Myoclonic encephalopathy and diabetes mellitus in a boy. Dev Med Child Neurol. Jul 1999;41(7):489-90. [Medline].

  23. Lernmark A. Glutamic acid decarboxylase--gene to antigen to disease. J Intern Med. Nov 1996;240(5):259-77. [Medline].

  24. Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med. Oct 5 1999;131(7):522-30. [Medline][Full Text].

  25. Lohmann T, Hawa M, Leslie RD, et al. Immune reactivity to glutamic acid decarboxylase 65 in stiffman syndrome and type 1 diabetes mellitus. Lancet. Jul 1 2000;356(9223):31-5. [Medline].

  26. Lynex CN, Carr IM, Leek JP. Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders. BMC Neurol. Nov 30 2004;4(1):20. [Medline].

  27. Martino G, Grimaldi LM, Bazzigaluppi E. The insulin-dependent diabetes mellitus-associated ICA 105 autoantigen in stiff-man syndrome patients. J Neuroimmunol. Sep 1996;69(1-2):129-34. [Medline].

  28. Meinck HM, Ricker K, Hulser PJ, et al. Stiff man syndrome: clinical and laboratory findings in eight patients. J Neurol. Jan 1994;241(3):157-66. [Medline].

  29. Mitoma H, Song SY, Ishida K. Presynaptic impairment of cerebellar inhibitory synapses by an autoantibody to glutamate decarboxylase. J Neurol Sci. Apr 1 2000;175(1):40-4. [Medline].

  30. Moersch FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm ('stiff-man syndrome'): report of a case and some observations in 13 other cases. Mayo Clin Proc. 1956;31:421-7.

  31. Nicholas AP, Chatterjee A, Arnold MM. Stiff-persons'' syndrome associated with thymoma and subsequent myasthenia gravis. Muscle Nerve. Apr 1997;20(4):493-8. [Medline].

  32. Peltola J, Kulmala P, Isojarvi J. Autoantibodies to glutamic acid decarboxylase in patients with therapy- resistant epilepsy. Neurology. Jul 12 2000;55(1):46-50. [Medline].

  33. Raju R, Foote J, Banga JP. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol. Dec 1 2005;175(11):7755-62. [Medline].

  34. Saravanan PK, Paul J, Sayeed ZA. Stiff person syndrome and myasthenia gravis. Neurol India. Mar 2002;50(1):98-100. [Medline].

  35. Shariatmadar S, Noto TA. Plasma exchange in stiff-man syndrome. Ther Apher. Feb 2001;5(1):64-7. [Medline].

  36. Solimena M, Butler MH, De Camilli P. GAD, diabetes, and Stiff-Man syndrome: some progress and more questions. J Endocrinol Invest. Jul-Aug 1994;17(7):509-20. [Medline].

  37. Solimena M, De Camilli P. Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci. Oct 1991;14(10):452-7. [Medline].

  38. Sommer C, Weishaupt A, Brinkhoff J. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. Apr 16-22 2005;365(9468):1406-11. [Medline].

  39. Stayer C, Meinck HM. Stiff-man syndrome: an overview. Neurologia. Feb 1998;13(2):83-8. [Medline].

  40. Takenoshita H, Shizuka-Ikeda M, Mitoma H, et al. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry. Mar 2001;70(3):386-9. [Medline][Full Text].

  41. Vincent A, Grimaldi LM, Martino G, et al. Antibodies to 125I-glutamic acid decarboxylase in patients with stiff man syndrome. J Neurol Neurosurg Psychiatry. Apr 1997;62(4):395-7. [Medline].

  42. Warich-Kirches M, Von Bossanyi P, Treuheit T. Stiff-man syndrome: possible autoimmune etiology targeted against GABA-ergic cells. Clin Neuropathol. Jul-Aug 1997;16(4):214-9. [Medline].

  43. Ziegler B, Strebelow M, Rjasanowski I, et al. A monoclonal antibody-based characterization of autoantibodies against glutamic acid decarboxylase in adults with latent autoimmune diabetes. Autoimmunity. 1998;28(2):61-8. [Medline].

Further Reading

Keywords

SPS, stiff man syndrome, SMS, stiff baby syndrome, SBS, hyperekplexia, Moersch-Woltmann syndrome, stiff woman syndrome, stiff limb syndrome

Contributor Information and Disclosures

Author

Nancy Rodgers-Neame, MD, Assistant Professor, Department of Pharmacology and Therapeutics, University of South Florida, Florida Comprehensive Epilepsy and Seizure Disorders Program
Nancy Rodgers-Neame, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Medical Women's Association, American Society for Clinical Pharmacology and Therapeutics, American Society for Pharmacology and Experimental Therapeutics, Society for Neuroscience, Southern Clinical Neurological Society, and Southern Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Paul E Barkhaus, MD, Professor, Department of Neurology, Medical College of Wisconsin; Director of Neuromuscular Diseases, Milwaukee Veterans Administration Medical Center
Paul E Barkhaus, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Neurological Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Glenn Lopate, MD, Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Chief of Neurology, St Louis ConnectCare, Consulting Staff, Barnes Jewish Hospital
Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa
Disclosure: Nothing to disclose.

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants
Nicholas Y Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Neurology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.